Ophthalmology Biosimilars Market: Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Ophthalmology Biosimilars Market: Molecule Type (Aflibercept, Bevacizumab, Ranibizumab, Adalimumab), Disease Type (Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion,  Others), and Geography

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

1. Executive Summary
2. Global Ophthalmology Biosimilars Market Introduction
2.1. Global Ophthalmology Biosimilars Market – Taxonomy
2.2. Global Ophthalmology Biosimilars Market –Definitions
2.2.1. Molecule Type
2.2.2. Disease Type
2.2.3. Region
3. Global Ophthalmology Biosimilars Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Ophthalmology Biosimilars Market Dynamic Factors – Impact Analysis
3.6. Impact of COVID 19 on The Market
3.7. Three Forecast Scenarios – Pessimistic, Conservative, and Opportunistic
3.8. Mapping Market Players’ Activities
3.9. Recent Key Developments
3.10. Financial Status of the Market Players
3.11. Recent Acquisitions, Collaborations, and Mergers
4. Global Ophthalmology Biosimilars Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Ophthalmology Biosimilars Market Forecast, By Molecule Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1. Aflibercept
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Bevacizumab
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Ranibizumab
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Adalimumab
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
6. Global Ophthalmology Biosimilars Market Forecast, By Disease Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1. Age-related Macular Degenration
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Diabetic Macular Edema
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Retinal Vein Occlusion
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Others
6.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
7. Global Ophthalmology Biosimilars Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.1. North America
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Ophthalmology Biosimilars Market – Opportunity Analysis Index, By Molecule Type, Distribution Channel, End User, and Region, 2022 – 2028
8. North America Ophthalmology Biosimilars Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.1. Molecule Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
8.1.1. Aflibercept
8.1.2. Bevacizumab
8.1.3. Ranibizumab
8.1.4. Adalimumab
8.2. Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
8.2.1. Age-related Macular Degenration
8.2.2. Diabetic Macular Edema
8.2.3. Retinal Vein Occlusion
8.2.4. Others
8.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
8.3.1. U.S.
8.3.2. Canada
8.4. North America Ophthalmology Biosimilars Market – Opportunity Analysis Index, By Molecule Type, Disease Type and Country, 2022 – 2028
8.5. North America Ophthalmology Biosimilars Market Dynamics – Trends
9. Europe Ophthalmology Biosimilars Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.1. Molecule Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
9.1.1. Aflibercept
9.1.2. Bevacizumab
9.1.3. Ranibizumab
9.1.4. Adalimumab
9.2. Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Age-related Macular Degenration
9.2.2. Diabetic Macular Edema
9.2.3. Retinal Vein Occlusion
9.2.4. Others
9.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Europe Ophthalmology Biosimilars Market – Opportunity Analysis Index, By Molecule Type, Disease Type and Country, 2022 – 2028
9.5. Europe Ophthalmology Biosimilars Market Dynamics – Trends
10. Asia-Pacific Ophthalmology Biosimilars Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
10.1. Molecule Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.1.1. Aflibercept
10.1.2. Bevacizumab
10.1.3. Ranibizumab
10.1.4. Adalimumab
10.2. Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Age-related Macular Degenration
10.2.2. Diabetic Macular Edema
10.2.3. Retinal Vein Occlusion
10.2.4. Others
10.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
10.3.1. Japan
10.3.2. China
10.3.3. India
10.3.4. ASEAN
10.3.5. Rest of Asia-Pacific
10.4. Asia-Pacific Ophthalmology Biosimilars Market – Opportunity Analysis Index, By Molecule Type, Disease Type and Country, 2022 – 2028
10.5. Asia-Pacific Ophthalmology Biosimilars Market Dynamics – Trends
11. Latin America Ophthalmology Biosimilars Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
11.1. Molecule Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.1.1. Aflibercept
11.1.2. Bevacizumab
11.1.3. Ranibizumab
11.1.4. Adalimumab
11.2. Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Age-related Macular Degenration
11.2.2. Diabetic Macular Edema
11.2.3. Retinal Vein Occlusion
11.2.4. Others
11.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
11.3.1. Brazil
11.3.2. Argentina
11.3.3. Rest of Latin America
11.4. Latin America Ophthalmology Biosimilars Market – Opportunity Analysis Index, By Molecule Type, Disease Type and Country, 2022 – 2028
11.5. Latin America Ophthalmology Biosimilars Market Dynamics – Trends
12. Middle East and Africa Ophthalmology Biosimilars Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
12.1. Molecule Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.1.1. Aflibercept
12.1.2. Bevacizumab
12.1.3. Ranibizumab
12.1.4. Adalimumab
12.2. Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Age-related Macular Degenration
12.2.2. Diabetic Macular Edema
12.2.3. Retinal Vein Occlusion
12.2.4. Others
12.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
12.3.1. Saudi Arabia
12.3.2. GCC Countries
12.3.3. South Africa
12.3.4. Rest of MEA
12.4. MEA Ophthalmology Biosimilars Market – Opportunity Analysis Index, By Molecule Type, Disease Type and Country, 2022 – 2028
12.5. MEA Ophthalmology Biosimilars Market Dynamics – Trends
13. Competition Landscape 
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Molecule Type Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Amgen
13.2.2. Boehringer Ingelheim
13.2.3. Samsung Bioepis
13.2.4. Hetero Drugs
13.2.5. Novartis AG
13.2.6. Intas Pharmaceuticals Ltd.
13.2.7. Xbrane Biopharma
13.2.8. Formycon AG
13.2.9. Zydus Cadila
13.2.10. Biocon
13.2.11. mAbxience
14. Research Methodology
15. Key Assumptions and Acronyms

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Company Profile

  • Amgen
  • Boehringer Ingelheim
  • Samsung Bioepis
  • Hetero Drugs
  • Novartis AG
  • Intas Pharmaceuticals Ltd.
  • Xbrane Biopharma
  • Formycon AG
  • Zydus Cadila
  • Biocon
  • mAbxiencee

Description

1. Executive Summary
2. Global Ophthalmology Biosimilars Market Introduction
2.1. Global Ophthalmology Biosimilars Market – Taxonomy
2.2. Global Ophthalmology Biosimilars Market –Definitions
2.2.1. Molecule Type
2.2.2. Disease Type
2.2.3. Region
3. Global Ophthalmology Biosimilars Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Ophthalmology Biosimilars Market Dynamic Factors – Impact Analysis
3.6. Impact of COVID 19 on The Market
3.7. Three Forecast Scenarios – Pessimistic, Conservative, and Opportunistic
3.8. Mapping Market Players’ Activities
3.9. Recent Key Developments
3.10. Financial Status of the Market Players
3.11. Recent Acquisitions, Collaborations, and Mergers
4. Global Ophthalmology Biosimilars Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Ophthalmology Biosimilars Market Forecast, By Molecule Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1. Aflibercept
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Bevacizumab
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Ranibizumab
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Adalimumab
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
6. Global Ophthalmology Biosimilars Market Forecast, By Disease Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1. Age-related Macular Degenration
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Diabetic Macular Edema
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Retinal Vein Occlusion
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Others
6.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
7. Global Ophthalmology Biosimilars Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.1. North America
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Ophthalmology Biosimilars Market – Opportunity Analysis Index, By Molecule Type, Distribution Channel, End User, and Region, 2022 – 2028
8. North America Ophthalmology Biosimilars Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.1. Molecule Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
8.1.1. Aflibercept
8.1.2. Bevacizumab
8.1.3. Ranibizumab
8.1.4. Adalimumab
8.2. Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
8.2.1. Age-related Macular Degenration
8.2.2. Diabetic Macular Edema
8.2.3. Retinal Vein Occlusion
8.2.4. Others
8.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
8.3.1. U.S.
8.3.2. Canada
8.4. North America Ophthalmology Biosimilars Market – Opportunity Analysis Index, By Molecule Type, Disease Type and Country, 2022 – 2028
8.5. North America Ophthalmology Biosimilars Market Dynamics – Trends
9. Europe Ophthalmology Biosimilars Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.1. Molecule Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
9.1.1. Aflibercept
9.1.2. Bevacizumab
9.1.3. Ranibizumab
9.1.4. Adalimumab
9.2. Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Age-related Macular Degenration
9.2.2. Diabetic Macular Edema
9.2.3. Retinal Vein Occlusion
9.2.4. Others
9.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Europe Ophthalmology Biosimilars Market – Opportunity Analysis Index, By Molecule Type, Disease Type and Country, 2022 – 2028
9.5. Europe Ophthalmology Biosimilars Market Dynamics – Trends
10. Asia-Pacific Ophthalmology Biosimilars Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
10.1. Molecule Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.1.1. Aflibercept
10.1.2. Bevacizumab
10.1.3. Ranibizumab
10.1.4. Adalimumab
10.2. Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Age-related Macular Degenration
10.2.2. Diabetic Macular Edema
10.2.3. Retinal Vein Occlusion
10.2.4. Others
10.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
10.3.1. Japan
10.3.2. China
10.3.3. India
10.3.4. ASEAN
10.3.5. Rest of Asia-Pacific
10.4. Asia-Pacific Ophthalmology Biosimilars Market – Opportunity Analysis Index, By Molecule Type, Disease Type and Country, 2022 – 2028
10.5. Asia-Pacific Ophthalmology Biosimilars Market Dynamics – Trends
11. Latin America Ophthalmology Biosimilars Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
11.1. Molecule Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.1.1. Aflibercept
11.1.2. Bevacizumab
11.1.3. Ranibizumab
11.1.4. Adalimumab
11.2. Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Age-related Macular Degenration
11.2.2. Diabetic Macular Edema
11.2.3. Retinal Vein Occlusion
11.2.4. Others
11.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
11.3.1. Brazil
11.3.2. Argentina
11.3.3. Rest of Latin America
11.4. Latin America Ophthalmology Biosimilars Market – Opportunity Analysis Index, By Molecule Type, Disease Type and Country, 2022 – 2028
11.5. Latin America Ophthalmology Biosimilars Market Dynamics – Trends
12. Middle East and Africa Ophthalmology Biosimilars Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
12.1. Molecule Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.1.1. Aflibercept
12.1.2. Bevacizumab
12.1.3. Ranibizumab
12.1.4. Adalimumab
12.2. Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Age-related Macular Degenration
12.2.2. Diabetic Macular Edema
12.2.3. Retinal Vein Occlusion
12.2.4. Others
12.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
12.3.1. Saudi Arabia
12.3.2. GCC Countries
12.3.3. South Africa
12.3.4. Rest of MEA
12.4. MEA Ophthalmology Biosimilars Market – Opportunity Analysis Index, By Molecule Type, Disease Type and Country, 2022 – 2028
12.5. MEA Ophthalmology Biosimilars Market Dynamics – Trends
13. Competition Landscape 
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Molecule Type Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Amgen
13.2.2. Boehringer Ingelheim
13.2.3. Samsung Bioepis
13.2.4. Hetero Drugs
13.2.5. Novartis AG
13.2.6. Intas Pharmaceuticals Ltd.
13.2.7. Xbrane Biopharma
13.2.8. Formycon AG
13.2.9. Zydus Cadila
13.2.10. Biocon
13.2.11. mAbxience
14. Research Methodology
15. Key Assumptions and Acronyms

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX